Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology

被引:0
|
作者
Fen Pei
Hongchun Li
Mark J. Henderson
Steven A. Titus
Ajit Jadhav
Anton Simeonov
Murat Can Cobanoglu
Seyed H. Mousavi
Tongying Shun
Lee McDermott
Prema Iyer
Michael Fioravanti
Diane Carlisle
Robert M. Friedlander
Ivet Bahar
D. Lansing Taylor
Timothy R. Lezon
Andrew M. Stern
Mark E. Schurdak
机构
[1] Department of Computational and Systems Biology,
[2] University of Pittsburgh,undefined
[3] National Center for Advancing Translational Sciences,undefined
[4] National Institutes of Health,undefined
[5] Department of Neurological Surgery,undefined
[6] University of Pittsburgh,undefined
[7] University of Pittsburgh Drug Discovery Institute,undefined
[8] Department of Pharmaceutical Sciences,undefined
[9] University of Pittsburgh,undefined
[10] University of Pittsburgh Brain Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Quantitative Systems Pharmacology (QSP) is a drug discovery approach that integrates computational and experimental methods in an iterative way to gain a comprehensive, unbiased understanding of disease processes to inform effective therapeutic strategies. We report the implementation of QSP to Huntington’s Disease, with the application of a chemogenomics platform to identify strategies to protect neuronal cells from mutant huntingtin induced death. Using the STHdhQ111 cell model, we investigated the protective effects of small molecule probes having diverse canonical modes-of-action to infer pathways of neuronal cell protection connected to drug mechanism. Several mechanistically diverse protective probes were identified, most of which showed less than 50% efficacy. Specific combinations of these probes were synergistic in enhancing efficacy. Computational analysis of these probes revealed a convergence of pathways indicating activation of PKA. Analysis of phospho-PKA levels showed lower cytoplasmic levels in STHdhQ111 cells compared to wild type STHdhQ7 cells, and these levels were increased by several of the protective compounds. Pharmacological inhibition of PKA activity reduced protection supporting the hypothesis that protection may be working, in part, through activation of the PKA network. The systems-level studies described here can be broadly applied to any discovery strategy involving small molecule modulation of disease phenotype.
引用
收藏
相关论文
共 50 条
  • [31] QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF AMYLOID BETA AND PLAQUE DYNAMICS IN ALZHEIMER'S DISEASE UPON TREATMENT WITH CRENEZUMAB, SOLANEZUMAB, AND BAPINEUZUMAB.
    Lin, L.
    Madrasi, K.
    Abdul, H.
    Young, C.
    Park, J.
    Burke, J.
    Apgar, J.
    Hua, F.
    Gruenbaum, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S104 - S104
  • [32] QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF AMYLOID BETA AND PLAQUE DYNAMICS IN ALZHEIMER'S DISEASE UPON TREATMENT WITH CRENEZUMAB, SOLANEZUMAB, AND BAPINEUZUMAB.
    Lin, L.
    Madrasi, K.
    Abdul, H.
    Young, C.
    Park, J.
    Burke, J.
    Apgar, J.
    Hua, F.
    Gruenbaum, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S11 - S11
  • [33] Delivery of BDNF through a Pluripotent Stem Cell-Based Platform Ameliorates Behavioral Deficits in a Mouse Model of Huntington's Disease
    Selvaraj, Sridhar
    Simmons, Danielle A.
    Chen, Tingshuo
    Cao, Gloria Y.
    Camelo, Talita S.
    McHugh, Tyne L. M.
    Gonzalez, Selena
    Martin, Renata M.
    Simanauskaite, Juste M.
    Uchida, Nobuko
    Longo, Frank M.
    Porteus, Matthew H.
    MOLECULAR THERAPY, 2023, 31 (04) : 18 - 18
  • [34] Δ9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE
    Zeissler, Marie-Louise
    Eastwood, Jordan
    Hanemann, C. Oliver
    Zajicek, John
    Carroll, Camille
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (11):
  • [35] Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model
    Geerts, Hugo
    Spiros, Athan
    Roberts, Patrick
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [36] Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
    Hugo Geerts
    Athan Spiros
    Patrick Roberts
    Alzheimer's Research & Therapy, 10
  • [37] A Human Induced Pluripotent Stem Cell-Derived Isogenic Model of Huntington's Disease Based on Neuronal Cells Has Several Relevant Phenotypic Abnormalities
    Malankhanova, Tuyana
    Suldina, Lyubov
    Grigor'eva, Elena
    Medvedev, Sergey
    Minina, Julia
    Morozova, Ksenia
    Kiseleva, Elena
    Zakian, Suren
    Malakhova, Anastasia
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 26
  • [38] Protective effects of activated signaling pathways by insulin on C6 glial cell model of MPP+-induced Parkinson's disease
    Ramalingam, Mahesh
    Kim, Sung-Jin
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2017, 37 (01) : 100 - 107
  • [39] SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease (vol 7, 8, 2022)
    Park, Hyun Jung
    Han, Areum
    Kim, Ji Yeon
    Choi, Jiwoo
    Bae, Hee Sook
    Cho, Gyu-bon
    Shin, Hyejung
    Shin, Eun Ji
    Lee, Kang-in
    Kim, Seokjoong
    Lee, Jae Young
    Song, Jihwan
    NPJ REGENERATIVE MEDICINE, 2022, 7 (01)
  • [40] Quantitative Systems Pharmacology Model of Sickle Cell Disease and Response to Gene Editing Therapy to Support Clinical Development of SAR445136 (BIVV003)
    Kaddi, Chanchala
    Holz, Danielle
    Tao, Mengdi
    Galeon, Isobelle
    Reiner, David
    Rendo, Pablo
    Zaph, Susana
    BLOOD, 2021, 138 : 1860 - +